Effect of Metformin on Doxorubicin-Induced Memory Dysfunction

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Doxorubicin (DOX) is a vital chemotherapy agent, but frequently causes cognitive dysfunction (chemobrain) in cancer survivors.
• Chemobrain affects a significant portion of survivors, with no current effective treatments, highlighting an urgent need for therapeutic interventions.

Purpose of the Study:

• To investigate the neuroprotective potential of metformin (MET) against doxorubicin-induced cognitive deficits.
• To evaluate if metformin can mitigate the learning and memory impairments associated with doxorubicin treatment.

Main Methods:

• Forty male rats were allocated into four groups: control, DOX, DOX + MET, and MET.
• DOX was administered weekly at 4 mg/kg for five weeks (cumulative dose: 20 mg/kg).
• Metformin was administered via drinking water to relevant groups, followed by behavioral and glucose level assessments.

Main Results:

• Doxorubicin treatment significantly impaired learning and memory in behavioral tests, including the Y-maze, novel object recognition, and elevated plus maze.
• Metformin administration did not reverse or alleviate the doxorubicin-induced cognitive deficits.
• Neither doxorubicin nor metformin affected glucose levels in the tested groups.

Conclusions:

• Doxorubicin treatment induces significant memory impairment in a rat model.
• Metformin does not demonstrate efficacy in preventing or treating doxorubicin-induced neurotoxicity and cognitive dysfunction.
• Further research is needed to identify effective therapeutic strategies for chemobrain.